Tafamidis ATTR denied for missing prior authorization by Aetna?

Aetna's specific coverage criteria for tafamidis attr are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Requires Prior Authorization for Tafamidis — and How to Navigate It

Prior authorization (PA) is Aetna's gatekeeping mechanism for high-cost specialty drugs. A PA-required denial does not mean Aetna considers tafamidis inappropriate — it means the prescription was dispensed or billed before formal approval was obtained, or a submitted PA request was incomplete. For ATTR-CM, PA requirements typically focus on confirming the diagnosis, disease stage, and prescriber specialty. The good news: because there is no formulary-equivalent alternative, a well-documented PA request has a strong foundation.

## Your Federal Appeal Rights

• ACA §2719 External Review: If Aetna denies the PA request and your internal appeal fails, independent external review is available within approximately four months of the final denial. Check your denial notice for the precise deadline.
• ERISA §503: Employer-plan members may demand the specific clinical criteria applied, a full-and-fair review, and written reasons citing plan language.
• Expedited PA and Appeal: If waiting for a standard PA decision could seriously harm your health, federal law requires Aetna to issue an expedited decision (generally within 72 hours). Request this in writing at the same time you appeal.

## Concrete Appeal Steps and Timeline

1. Confirm whether a PA was ever submitted — check with the prescriber's office and the pharmacy. 2. If no PA was submitted, initiate the PA process through Aetna's provider portal immediately; retroactive PA requests are sometimes possible. 3. If a PA was denied, file a Level 1 internal appeal with complete supporting documentation. 4. Ask the prescriber to request a peer-to-peer call with Aetna's reviewing physician — this resolves many PA denials before a formal appeal is necessary. 5. If internally upheld, escalate to Level 2 and then to external review within the deadline.

## Documentation to Gather

• Diagnosis documentation: Confirmatory testing for ATTR-CM (nuclear imaging, biopsy, or genetic testing as applicable), clearly linking the diagnosis to the FDA-approved indication for tafamidis.
• Prescriber specialty confirmation: Aetna commonly requires that tafamidis be prescribed by or in consultation with a cardiologist or specialist experienced in amyloidosis.
• Clinical severity evidence: Chart notes documenting functional classification, symptom burden, and disease progression.
• Letter of medical necessity: Should explicitly address each PA criterion listed in Aetna's Clinical Policy Bulletin — obtain the bulletin first and build the letter around it.
• Prior treatment summary: Dates and outcomes of any cardiac therapies previously used.

## Criteria-Mapping Structure

Request Aetna's PA criteria checklist before drafting the appeal. Map each criterion to a specific chart entry: date of test, test type, result, and ordering physician's interpretation. Submit this as a structured cover sheet so the reviewer can check off each requirement without additional follow-up. Completeness at the first submission is the single most effective way to avoid a second denial cycle.